Table 2 HPV and HIV-co-infection at 3 anatomical sites among MSM in Cape Town, South Africa
HPV type classification | ANAL (n = 191) | ORO-PHARYNGEAL (n = 200) | URINE (n = 190) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total (%) | HIV- (n = 106) | HIV+ (n = 85) | P-value | Total (%) | HIV- (n = 112) | HIV+ (n = 88) | P-value | Total (%) | HIV- (n = 107) | HIV+ (n = 83) | P-value | |
No type | 52 (27.2) | 45 (42.4) | 7 (8.2) | Ë‚0.001 | 177 (88.5) | 104 (92.9) | 73 (83.0) | 0.029 | 161 (84.7) | 91 (85.1) | 70 (84.3) | 0.892 |
Any type | 139 (72.8) | 61 (57.6) | 78 (91.8) | Ë‚0.001 | 23 (11.5) | 8 (7.1) | 15 (17.1) | 0.029 | 29 (15.3) | 16 (14.3) | 13 (14.8) | 0.892 |
Single type | 26 (13.6) | 21 (19.8) | 5 (5.9) | 0.005 | 16 (8.0) | 6 (5.4) | 10 (11.4) | 0.120 | 22 (11.6) | 14 (12.5) | 8 (9.1) | 0.461 |
Multiple types | 113 (59.2) | 40 (37.7) | 73 (85.9) | Ë‚0.001 | 7 (3.5) | 2 (1.8) | 5 (5.7) | 0.136 | 7 (3.7) | 2 (1.8) | 5 (5.7) | 0.131 |
LR-HPV | 126 (66.0) | 50 (47.2) | 76 (89.4) | Ë‚0.001 | 14 (7.0) | 4 (3.6) | 10 (11.4) | 0.032 | 19 (10.0) | 8 (7.5) | 11 (13.3) | 0.188 |
HR-HPV | 110 (57.6) | 41 (38.7) | 69 (81.2) | Ë‚0.001 | 15 (7.5) | 6 (5.4) | 9 (10.2) | 0.194 | 15 (7.9) | 9 (8.4) | 6 (7.2) | 0.764 |
HPV-6/11 | 50 (26.2) | 19 (17.9) | 31 (36.5) | 0.003 | 3 (1.5) | 1 (0.9) | 2 (2.3) | 0.425 | 3 (1.6) | 0 (0.0) | 3 (3.6) | 0.047 |
HPV-16/18 | 55 (28.8) | 19 (17.9) | 36 (42.4) | Ë‚0.001 | 6 (3.0) | 3 (2.7) | 3 (3.4) | 0.763 | 3 (1.6) | 2 (1.9) | 1 (1.2) | 0.715 |
HPV-6/11/16/18 | 77 (40.3) | 30 (28.3) | 47 (55.3) | Ë‚0.001 | 9 (4.5) | 4 (3.6) | 5 (5.7) | 0.474 | 6 (3.2) | 2 (1.9) | 4 (4.8) | 0.248 |
HPV-31/33/45 | 50 (26.2) | 14 (13.2) | 36 (42.4) | Ë‚0.001 | 3 (1.5) | 0 (0.0) | 3 (3.4) | 0.048 | 5 (2.6) | 3 (2.8) | 2 (2.4) | 0.866 |
HPV-6/11/16/18/31/33/45 | 98 (51.3) | 36 (34.0) | 62 (72.9) | Ë‚0.001 | 11 (5.5) | 4 (3.6) | 7 (8.0) | 0.177 | 10 (5.3) | 5 (4.7) | 5 (6.0) | 0.679 |